Skip to content
RNAWiki
Checking…
All public datasets

Public dataset

Recorded source agreement and disagreement

Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.

What this does not mean: agree can mean only that sources print the same normalized reading; it is not clinical-context equivalence, independent replication, or proof. differ requires matching structured context and disjoint comparable values. not_comparable and insufficient_context are not disagreement.
Public rows
1,681
Generated
Schema version
source-consensus/2

Coverage

What this run contains

Compared medicine fields
1,681
Agree
1,282
Differ
0
Not comparable
12
Insufficient context
387
Fields represented
5
bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution

Method

How the rows were made

  1. Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
  2. One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
  3. Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
  4. not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
  5. The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
  6. Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
  7. documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.

Limits

Read these before using a row

  • Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
  • The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
  • Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
  • Only the recorded fields and source documents in this snapshot are compared.
  • A source count is the number of retained source records in the row, not a count of independent experiments.

Provenance

Source examples

abacavir · bioavailability · agree

15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
The geometric mean absolute bioavailability of the tablet was 83%.

alemtuzumab · volumeOfDistribution · not_comparable

2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)
Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).

abiraterone · halfLife · insufficient_context

31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.

Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

FieldTypeMeaning
medicineSlugstringStable RNAWiki medicine route key.
fieldstringRecorded pharmacokinetic field being compared.
comparisonStatestringagree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero.
comparisonReasonsstring[]Deterministic codes explaining the state.
documentsExaminednumberRecorded source documents considered for the field.
sourceCountnumberRecorded source readings represented.
agreementRatenumberShare represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability.
readingsconsensus-reading[]Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt.

Reader

Search and filter the rows

Case-insensitive text search over the public fields named for this dataset.

Exact comparability state.

Exact recorded field key.

Clear

Showing 801–810 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

  1. Projected row 801

    Medicine slug
    ketoconazole
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    59
    Source count
    12
    Agreement rate
    1
    Recorded readings

    1. 2 hours

      Numeric value
      2
      Unit
      hours
      Source records
      12

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 12 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1d598696-c6f3-4b7c-ad73-949d2089df35 (opens source in a new tab)

        Ketoconazole label

        Version not recorded · Effective date not recorded

        Elimination Elimination from plasma is biphasic with a half-life of 2 hours during the first 10 hours and 8 hours thereafter.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3ea8a22b-cd61-4623-a11f-43e3396b50fa (opens source in a new tab)

        Ketoconazole label

        Version not recorded · Effective date not recorded

        Elimination Elimination from plasma is biphasic with a half-life of 2 hours during the first 10 hours and 8 hours thereafter.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f5dc1e67-639f-5476-e053-2995a90a4210 (opens source in a new tab)

        Ketoconazole label

        Version not recorded · Effective date not recorded

        Elimination Elimination from plasma is biphasic with a half-life of 2 hours during the first 10 hours and 8 hours thereafter.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f162e616-21b4-49b1-b437-15e21001a6f0 (opens source in a new tab)

        Ketoconazole label

        Version not recorded · Effective date not recorded

        Elimination Elimination from plasma is biphasic with a half-life of 2 hours during the first 10 hours and 8 hours thereafter.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:369f31da-d3c3-49b8-956f-f70598760164 (opens source in a new tab)

        Ketoconazole label

        Version not recorded · Effective date not recorded

        Elimination Elimination from plasma is biphasic with a half-life of 2 hours during the first 10 hours and 8 hours thereafter.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8ca815a8-bccb-4ee2-a042-922373329cae (opens source in a new tab)

        Ketoconazole label

        Version not recorded · Effective date not recorded

        Elimination Elimination from plasma is biphasic with a half-life of 2 hours during the first 10 hours and 8 hours thereafter.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:517c29fc-2a2a-4bd5-a8bb-b464a65d2be0 (opens source in a new tab)

        Ketoconazole label

        Version not recorded · Effective date not recorded

        Elimination Elimination from plasma is biphasic with a half-life of 2 hours during the first 10 hours and 8 hours thereafter.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6d4be760-c723-4f54-a854-12c61cf91703 (opens source in a new tab)

        Ketoconazole label

        Version not recorded · Effective date not recorded

        Elimination Elimination from plasma is biphasic with a half-life of 2 hours during the first 10 hours and 8 hours thereafter.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:57e81e13-b395-4dbd-b660-3038de41a838 (opens source in a new tab)

        Ketoconazole label

        Version not recorded · Effective date not recorded

        Elimination Elimination from plasma is biphasic with a half-life of 2 hours during the first 10 hours and 8 hours thereafter.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bc189ce2-3f10-260d-e053-2a95a90ae808 (opens source in a new tab)

        Ketoconazole label

        Version not recorded · Effective date not recorded

        Elimination Elimination from plasma is biphasic with a half-life of 2 hours during the first 10 hours and 8 hours thereafter.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a9fc4618-4d87-47ef-ab3c-c9ffac3ba9b7 (opens source in a new tab)

        Ketoconazole label

        Version not recorded · Effective date not recorded

        Elimination Elimination from plasma is biphasic with a half-life of 2 hours during the first 10 hours and 8 hours thereafter.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4baebcab-a237-42c0-9183-6f447a44e371 (opens source in a new tab)

        Ketoconazole label

        Version not recorded · Effective date not recorded

        Elimination Elimination from plasma is biphasic with a half-life of 2 hours during the first 10 hours and 8 hours thereafter.

  2. Projected row 802

    Medicine slug
    ketoconazole
    Compared field
    proteinBinding
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    59
    Source count
    12
    Agreement rate
    1
    Recorded readings

    1. 99%

      Numeric value
      99
      Unit
      %
      Source records
      12

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 12 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1d598696-c6f3-4b7c-ad73-949d2089df35 (opens source in a new tab)

        Ketoconazole label

        Version not recorded · Effective date not recorded

        Distribution In vitro, the plasma protein binding is about 99% mainly to the albumin fraction.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3ea8a22b-cd61-4623-a11f-43e3396b50fa (opens source in a new tab)

        Ketoconazole label

        Version not recorded · Effective date not recorded

        Distribution In vitro, the plasma protein binding is about 99% mainly to the albumin fraction.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f5dc1e67-639f-5476-e053-2995a90a4210 (opens source in a new tab)

        Ketoconazole label

        Version not recorded · Effective date not recorded

        Distribution In vitro, the plasma protein binding is about 99% mainly to the albumin fraction.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f162e616-21b4-49b1-b437-15e21001a6f0 (opens source in a new tab)

        Ketoconazole label

        Version not recorded · Effective date not recorded

        Distribution In vitro , the plasma protein binding is about 99% mainly to the albumin fraction.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:369f31da-d3c3-49b8-956f-f70598760164 (opens source in a new tab)

        Ketoconazole label

        Version not recorded · Effective date not recorded

        Distribution In vitro, the plasma protein binding is about 99% mainly to the albumin fraction.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8ca815a8-bccb-4ee2-a042-922373329cae (opens source in a new tab)

        Ketoconazole label

        Version not recorded · Effective date not recorded

        Distribution In vitro , the plasma protein binding is about 99% mainly to the albumin fraction.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:517c29fc-2a2a-4bd5-a8bb-b464a65d2be0 (opens source in a new tab)

        Ketoconazole label

        Version not recorded · Effective date not recorded

        Distribution In vitro, the plasma protein binding is about 99% mainly to the albumin fraction.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6d4be760-c723-4f54-a854-12c61cf91703 (opens source in a new tab)

        Ketoconazole label

        Version not recorded · Effective date not recorded

        Distribution In vitro , the plasma protein binding is about 99% mainly to the albumin fraction.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:57e81e13-b395-4dbd-b660-3038de41a838 (opens source in a new tab)

        Ketoconazole label

        Version not recorded · Effective date not recorded

        Distribution In vitro, the plasma protein binding is about 99% mainly to the albumin fraction.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bc189ce2-3f10-260d-e053-2a95a90ae808 (opens source in a new tab)

        Ketoconazole label

        Version not recorded · Effective date not recorded

        Distribution In vitro, the plasma protein binding is about 99% mainly to the albumin fraction.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a9fc4618-4d87-47ef-ab3c-c9ffac3ba9b7 (opens source in a new tab)

        Ketoconazole label

        Version not recorded · Effective date not recorded

        Distribution In vitro , the plasma protein binding is about 99% mainly to the albumin fraction.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4baebcab-a237-42c0-9183-6f447a44e371 (opens source in a new tab)

        Ketoconazole label

        Version not recorded · Effective date not recorded

        Distribution In vitro , the plasma protein binding is about 99% mainly to the albumin fraction.

  3. Projected row 803

    Medicine slug
    ketoconazole
    Compared field
    tMax
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    59
    Source count
    12
    Agreement rate
    1
    Recorded readings

    1. 1 to 4 hours

      Numeric value
      1
      Unit
      hours
      Source records
      12

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 12 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1d598696-c6f3-4b7c-ad73-949d2089df35 (opens source in a new tab)

        Ketoconazole label

        Version not recorded · Effective date not recorded

        Data from some clinical PK/PD studies and drug interaction studies suggest that oral dosing with ketoconazole at 200 mg twice daily for 3 to 7 days can result in an increase of the QT c interval: a mean maximum increase of about 6 to 12 msec was seen at ketoconazole peak plasma concentrations about 1 to 4 hours after ketoconazole administration.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3ea8a22b-cd61-4623-a11f-43e3396b50fa (opens source in a new tab)

        Ketoconazole label

        Version not recorded · Effective date not recorded

        Data from some clinical PK/PD studies and drug interaction studies suggest that oral dosing with ketoconazole at 200 mg twice daily for 3 to 7 days can result in an increase of the QT c interval: a mean maximum increase of about 6 to 12 msec was seen at ketoconazole peak plasma concentrations about 1 to 4 hours after ketoconazole administration.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f5dc1e67-639f-5476-e053-2995a90a4210 (opens source in a new tab)

        Ketoconazole label

        Version not recorded · Effective date not recorded

        Data from some clinical PK/PD studies and drug interaction studies suggest that oral dosing with ketoconazole at 200 mg twice daily for 3 to 7 days can result in an increase of the QTc interval: a mean maximum increase of about 6 to 12 msec was seen at ketoconazole peak plasma concentrations about 1 to 4 hours after ketoconazole administration.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f162e616-21b4-49b1-b437-15e21001a6f0 (opens source in a new tab)

        Ketoconazole label

        Version not recorded · Effective date not recorded

        Data from some clinical PK/PD studies and drug interaction studies suggest that oral dosing with ketoconazole at 200 mg twice daily for 3 to 7 days can result in an increase of the QT C interval: a mean maximum increase of about 6 to 12 msec was seen at ketoconazole peak plasma concentrations about 1 to 4 hours after ketoconazole administration.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:369f31da-d3c3-49b8-956f-f70598760164 (opens source in a new tab)

        Ketoconazole label

        Version not recorded · Effective date not recorded

        Data from some clinical PK/PO studies and drug interaction studies suggest that oral dosing with ketoconazole at 200 mg twice daily for 3 to 7 days can result in an increase of the QT interval: a mean maximum increase of about 6 to 12 msec was seen at ketoconazole peak plasma concentrations about 1 to 4 hours after ketoconazole administration.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8ca815a8-bccb-4ee2-a042-922373329cae (opens source in a new tab)

        Ketoconazole label

        Version not recorded · Effective date not recorded

        Data from some clinical PK/PD studies and drug interaction studies suggest that oral dosing with ketoconazole at 200 mg twice daily for 3 to 7 days can result in an increase of the QT c interval: a mean maximum increase of about 6 to 12 msec was seen at ketoconazole peak plasma concentrations about 1 to 4 hours after ketoconazole administration.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:517c29fc-2a2a-4bd5-a8bb-b464a65d2be0 (opens source in a new tab)

        Ketoconazole label

        Version not recorded · Effective date not recorded

        Data from some clinical PK/PD studies and drug interaction studies suggest that oral dosing with ketoconazole at 200 mg twice daily for 3 to 7 days can result in an increase of the QT c interval: a mean maximum increase of about 6 to 12 msec was seen at ketoconazole peak plasma concentrations about 1 to 4 hours after ketoconazole administration.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6d4be760-c723-4f54-a854-12c61cf91703 (opens source in a new tab)

        Ketoconazole label

        Version not recorded · Effective date not recorded

        Data from some clinical PK/PD studies and drug interaction studies suggest that oral dosing with ketoconazole at 200 mg twice daily for 3 to 7 days can result in an increase of the QT C interval: a mean maximum increase of about 6 to 12 msec was seen at ketoconazole peak plasma concentrations about 1 to 4 hours after ketoconazole administration.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:57e81e13-b395-4dbd-b660-3038de41a838 (opens source in a new tab)

        Ketoconazole label

        Version not recorded · Effective date not recorded

        Data from some clinical PK/PD studies and drug interaction studies suggest that oral dosing with ketoconazole at 200 mg twice daily for 3 to 7 days can result in an increase of the QT c interval: a mean maximum increase of about 6 to 12 msec was seen at ketoconazole peak plasma concentrations about 1 to 4 hours after ketoconazole administration.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bc189ce2-3f10-260d-e053-2a95a90ae808 (opens source in a new tab)

        Ketoconazole label

        Version not recorded · Effective date not recorded

        Data from some clinical PK/PD studies and drug interaction studies suggest that oral dosing with ketoconazole at 200 mg twice daily for 3 to 7 days can result in an increase of the QTc interval: a mean maximum increase of about 6 to 12 msec was seen at ketoconazole peak plasma concentrations about 1 to 4 hours after ketoconazole administration.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a9fc4618-4d87-47ef-ab3c-c9ffac3ba9b7 (opens source in a new tab)

        Ketoconazole label

        Version not recorded · Effective date not recorded

        Data from some clinical PK/PD studies and drug interaction studies suggest that oral dosing with ketoconazole at 200 mg twice daily for 3 to 7 days can result in an increase of the QT c interval: a mean maximum increase of about 6 to 12 msec was seen at ketoconazole peak plasma concentrations about 1 to 4 hours after ketoconazole administration.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4baebcab-a237-42c0-9183-6f447a44e371 (opens source in a new tab)

        Ketoconazole label

        Version not recorded · Effective date not recorded

        Data from some clinical PK/PD studies and drug interaction studies suggest that oral dosing with ketoconazole at 200 mg twice daily for 3 to 7 days can result in an increase of the QT c interval: a mean maximum increase of about 6 to 12 msec was seen at ketoconazole peak plasma concentrations about 1 to 4 hours after ketoconazole administration.

  4. Projected row 804

    Medicine slug
    ketoprofen
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    5
    Source count
    4
    Agreement rate
    1
    Recorded readings

    1. 2.05 ± 0.58 h

      Numeric value
      2.05
      Unit
      hours
      Source records
      4

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 4 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:47d0b808-7142-c7a9-e063-6394a90a6e0d (opens source in a new tab)

        Ketoprofen label

        Version not recorded · Effective date not recorded

        The elimination half-life of ketoprofen has been reported to be 2.05 ± 0.58 h (Mean ± S.D.) following IV administration from 2 to 4 hours following administration of ketoprofen capsules.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d0f47ab6-29ff-df07-e053-2a95a90a2b51 (opens source in a new tab)

        Ketoprofen label

        Version not recorded · Effective date not recorded

        The elimination half-life of ketoprofen has been reported to be 2.05 ± 0.58 h (Mean ± S.D.) following IV administration from 2 to 4 hours following administration of ketoprofen capsules.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4e7bceb6-dcb5-c5e0-e063-6294a90a101e (opens source in a new tab)

        Ketoprofen label

        Version not recorded · Effective date not recorded

        The elimination half-life of ketoprofen has been reported to be 2.05 ± 0.58 h (Mean ± S.D.) following IV administration from 2 to 4 hours following administration of ketoprofen capsules.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:492de5dc-7c1b-47be-8510-43be4e1fd4ed (opens source in a new tab)

        Ketoprofen label

        Version not recorded · Effective date not recorded

        The elimination half-life of ketoprofen has been reported to be 2.05 ± 0.58 h (Mean ± S.D.) following IV administration from 2 to 4 hours following administration of ketoprofen capsules.

  5. Projected row 805

    Medicine slug
    ketorolac
    Compared field
    bioavailability
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    146
    Source count
    108
    Agreement rate
    1
    Recorded readings

    1. 100%

      Numeric value
      100
      Unit
      %
      Source records
      108

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 108 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e0065781-ea33-4662-a8b1-c936e937ac9f (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Oral † Intramuscular* Intravenous Bolus ‡ Pharmacokinetic Parameters (units) 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:46dc8f62-e754-50e3-e054-00144ff8d46c (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ar Derived from IM pharmacokinetic studies in 54 normal volunteers Intravenous Bolus Derived from IV pharmacokinetic studies in 24 normal volunteers 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max Time-to-peak plasma concentration (min) 44 ± 34 33 ± 21 Mean value was simulated from observed plasma concentration data and standard deviation was simulated from percent coeffici
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:688f5dec-a6db-43c6-a1f8-5df99d08d395 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ng Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Pharmacokinetic Parameters (units) Oral 1 Intramuscular 2 Intravenous Bolus 3 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 6 (min) 44 ± 34 33 ± 21 4 44 ± 29 33 ± 21 4 1.1 ± 0.7 4 2.9 ± 1.8 C max 7 (mcg/mL) [single-dose] 0.87 ± 0.22 1.14 ± 0.32 4 2.42 ± 0.68 4.55 ± 1.27 4 2.47 ± 0.51 4 4.65 ± 0.96 C ma
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f4e7f1c8-e458-0860-e053-2a95a90a1bf0 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Pharmacokinetic Parameters (units) Oral * Intramuscular † Intravenous Bolus‡ 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% Tmax6 (min) 44 ± 34 33 ± 21§ 44 ± 29 33 ± 21§ 1.1 ± 0.74 2.9 ± 1.8 Cmax¶ (mcg/mL) [single-dose] 0.87 ± 0.22 1.14 ± 0.32 § 2.42 ± 0.68 4.55 ± 1.27§ 2.47 ± 0.51§ 4.65 ± 0.96 Cmax (mcg/mL)
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8f36fde8-bc59-4a59-8659-b173cfd15774 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        amuscular pharmacokinetic studies in 54 normal volunteers Intravenous Bolus Derived from intravenous pharmacokinetic studies in 24 normal volunteers 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max Time-to-peak plasma concentration (min) 44 ± 34 33 ± 21 Mean value was simulated from observed plasma concentration data and standard deviation was simulated from percent coeffici
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:862dd7b7-8ed5-42bf-870e-a45b86740226 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        asma concentration Average plasma concentration Volume of distribution Pharmacokinetic Parameters (units) Oral 1 Intramuscular 2 Intravenous Bolus 3 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 6 (min) 44 ± 34 33 ±21 4 44 ± 29 33 ± 21 4 1.1 ± 0.7 4 2.9 ± 1.8 C max 7 (mcg/mL) [single dose] 0.87 ± 0.22 1.14 ± 0.32 4 2.42 ± 0.68 4.55 ± 1.27 4 2.47 ± 0.51 4 4.65 ± 0.96 C max
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3f2956d9-9e68-f35e-e063-6394a90a706d (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        from percent coefficient of variation for observed C max and T max data Pharmacokinetic Parameters (units) Oral † Intramuscular* Intravenous Bolus ‡ 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2301a6a2-b88a-4c0d-bb6c-ad4a8af7da39 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ng Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Oral † Intramuscular * Intravenous Bolus ‡ Pharmacokinetic Parameters (units) 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:26a1761b-90bf-49c6-9e6a-f293af2296ce (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Pharmacokinetic Parameters (units) Oral † Intramuscular* Intravenous Bolus ‡ 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f335a030-ffa8-4f42-8166-2f06e036b40d (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Oral † Intramuscular* Intravenous Bolus ‡ Pharmacokinetic Parameters (units) 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8b26240c-b72b-42a6-ab33-a1e38224fbe0 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ar Derived from IM pharmacokinetic studies in 54 normal volunteers Intravenous Bolus Derived from IV pharmacokinetic studies in 24 normal volunteers 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max Time-to-peak plasma concentration (min) 44 ± 34 33 ± 21 Mean value was simulated from observed plasma concentration data and standard deviation was simulated from percent coeffici
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3855f527-fd6c-4f24-a4b4-cd47eec1193d (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ng Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Pharmacokinetic Parameters (units) Oral * Intramuscular † Intravenous Bolus ‡ 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max § (min) 44 ± 34 33 ± 21 ¶ 44 ± 29 33 ± 21 ¶ 1.1 ± 0.7 ¶ 2.9 ± 1.8 C max # (mcg/mL) [single dose] 0.87 ± 0.22 1.14 ± 0.32 ¶ 2.42 ± 0.68 4.55 ± 1.27 ¶ 2.47 ± 0.51 ¶ 4.65 ± 0.96 C ma
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6fa20b41-f860-4fea-b1fb-ab6d3fa34a90 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ar Derived from IM pharmacokinetic studies in 54 normal volunteers Intravenous Bolus Derived from IV pharmacokinetic studies in 24 normal volunteers 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% Tmax 6 (min) 44 ± 34 33 ± 21 Mean value was simulated from observed plasma concentration data and standard deviation was simulated from percent coefficient of variation for observed Cma
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ee44c322-4b4b-4397-a1a5-e5b3c3c5a053 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Pharmacokinetic Parameters (units) Oral † Intramuscular* Intravenous Bolus ‡ 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b88e562d-226b-4200-afa5-034e628c660f (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        from percent coefficient of variation for observed C max and T max data Pharmacokinetic Parameters (units) Oral † Intramuscular* Intravenous Bolus ‡ 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f5170993-81a9-4eb7-95ac-60697a5ee1d7 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ollowing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Pharmacokinetic Parameters (units) Oral Intramuscular Intravenous Bolus 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max (min) 44 ± 34 33 ± 21 44 ± 29 33 ± 21 1.1 ± 0.7 2.9 ± 1.8 C max (mcg/mL) [single-dose] 0.87 ± 0.22 1.14 ± 0.32 2.42 ± 0.68 4.55 ± 1.27 2.47 ± 0.51 4.65 ± 0.96 C max (mcg/mL) [stea
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f713500a-20b8-8e20-c4cc-956805170335 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ng Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Pharmacokinetic Parameters (units) Oral 1 Intramuscular 2 Intravenous Bolus 3 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 6 (min) 44 ± 34 33 ± 214 44 ± 29 33 ± 214 1.1 ± 0.74 2.9 ± 1.8 C max 7 (mcg/mL) [single-dose] 0.87 ± 0.22 1.14 ± 0.324 2.42 ± 0.68 4.55 ± 1.274 2.47 ± 0.514 4.65 ± 0.96 C max (mcg
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:18981677-8049-4864-b31c-96a299e3194d (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        amuscular pharmacokinetic studies in 54 normal volunteers Intravenous Bolus Derived from intravenous pharmacokinetic studies in 24 normal volunteers 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max Time-to-peak plasma concentration (min) 44 ± 34 33 ± 21 Mean value was simulated from observed plasma concentration data and standard deviation was simulated from percent coeffici
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ccf905ca-e164-4779-9485-2d139c821bad (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        from percent coefficient of variation for observed C max and T max data Oral † Intramuscular* Intravenous Bolus ‡ Pharmacokinetic Parameters (units) 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:48244614-53ec-47e6-ad48-50814bdcceb7 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ar Derived from IM pharmacokinetic studies in 54 normal volunteers Intravenous Bolus Derived from IV pharmacokinetic studies in 24 normal volunteers 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max Peak plasma concentration (min) 44 ± 34 33 ± 21 Time-to-peak plasma concentration 44 ± 29 33 ± 21 1.1 ± 0.7 2.9 ± 1.8 C max Not applicable because 60 mg is only recommended as a s
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6758cb38-dec8-468f-94e2-613772e39b9a (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Oral † Intramuscular* Intravenous Bolus ‡ Pharmacokinetic Parameters (units) 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54dec321-b4c9-f0d6-e063-6294a90ae231 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ted from percent coefficient of variation for observed Cmax and Tmax data Oral† Intramuscular* Intravenous Bolus‡ Pharmacokinetic Parameters (units) 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% Tmax1(min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 Cmax2(mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 Cmax (mcg/mL) [steady state qid] 1
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5734e81e-2471-1314-e063-6294a90ac9fe (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ar Derived from IM pharmacokinetic studies in 54 normal volunteers Intravenous Bolus Derived from IV pharmacokinetic studies in 24 normal volunteers 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% Tmax Time to peak plasma concentration (min) 44 ± 34 33 ± 21 Mean value was simulated from observed plasma concentration data and standard deviation was simulated from percent coefficie
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0749f61d-12e6-4280-8f41-bd4df81e7ae6 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ng Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Pharmacokinetic Parameters (units) Oral 1 Intramuscular 2 Intravenous Bolus 3 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 6 (min) 44 ± 34 33 ± 21 4 44 ± 29 33 ± 21 4 1.1 ± 0.7 4 2.9 ± 1.8 C max 7 (mcg/mL) [single-dose] 0.87 ± 0.22 1.14 ± 0.32 4 2.42 ± 0.68 4.55 ± 1.27 4 2.47 ± 0.51 4 4.65 ± 0.96 C ma
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ec6d453b-4b84-53d4-e053-2995a90a6006 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ar Derived from IM pharmacokinetic studies in 54 normal volunteers Intravenous Bolus Derived from IV pharmacokinetic studies in 24 normal volunteers 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% Tmax Time to peak plasma concentration (min) 44 ± 34 33 ± 21 Mean value was simulated from observed plasma concentration data and standard deviation was simulated from percent coefficie
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:10827042-a2d4-44f9-837d-2023a3d552ff (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ar Derived from IM pharmacokinetic studies in 54 normal volunteers Intravenous Bolus Derived from IV pharmacokinetic studies in 24 normal volunteers 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% Tmax Time to peak plasma concentration (min) 44 ± 34 33 ± 21 Mean value was simulated from observed plasma concentration data and standard deviation was simulated from percent coefficie
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:04df9620-6dcb-494a-83e2-6d28036be974 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        asma concentration Average plasma concentration Volume of distribution Pharmacokinetic Parameters (units) Oral 1 Intramuscular 2 Intravenous Bolus 3 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 6 (min) 44 ± 34 33 ±21 4 44 ± 29 33 ± 21 4 1.1 ± 0.7 4 2.9 ± 1.8 C max 7 (mcg/mL) [single dose] 0.87 ± 0.22 1.14 ± 0.32 4 2.42 ± 0.68 4.55 ± 1.27 4 2.47 ± 0.51 4 4.65 ± 0.96 C max
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5abd4389-4fb2-408b-a27e-cf64b6a921f1 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Pharmacokinetic Parameters (units) Oral † Intramuscular* Intravenous Bolus ‡ 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:29003279-8f27-bcdc-e063-6394a90aa639 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Oral † Intramuscular* Intravenous Bolus ‡ Pharmacokinetic Parameters (units) 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2cf7516b-ac86-ca72-e063-6394a90a4339 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Pharmacokinetic Parameters (units) Oral* Intramuscular † Intravenous Bolus ‡ 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44 ± 34 33 ± 21§ 44 ± 29 33 ± 21§ 1.1 ± 0.7§ 2.9 ± 1.8 C max 2 (mcg/mL) [single-dose] 0.87 ± 0.22 1.14 ± 0.32§ 2.42 ± 0.68 4.55 ± 1.27§ 2.47 ± 0.51§ 4.65 ± 0.96 C max (mcg
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cdd4d548-33f8-42d6-8eae-e36aa577c050 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        wing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Oral† Intramuscular* Intravenous Bolus ‡ Pharmacokinetic Parameters (units) 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3321b610-1c9b-4314-adbb-a2e163234dec (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Oral † Intramuscular* Intravenous Bolus ‡ Pharmacokinetic Parameters (units) 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:45966992-5af6-bf10-e063-6294a90af25b (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Pharmacokinetic Parameters (units) Oral † Intramuscular* Intravenous Bolus ‡ 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21 ** 44±29 33±21 ** 1.1±0.7 ** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87± 0.22 1.14± 0.32** 2.42±0.68 4.55±1.27 ** 2.47± 0.51 ** 4.65± 0.96 C max (mcg/mL) [ste
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:49dd153c-10e8-505b-e063-6394a90a595f (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Pharmacokinetic Parameters (units) Oral † Intramuscular* Intravenous Bolus ‡ 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:32198544-4a46-495c-ab65-0836dcbc2c49 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        from percent coefficient of variation for observed C max and T max data Pharmacokinetic Parameters (units) Oral † Intramuscular* Intravenous Bolus ‡ 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:51d443f8-716d-af3a-e063-6394a90a56a3 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ar Derived from IM pharmacokinetic studies in 54 normal volunteers Intravenous Bolus Derived from IV pharmacokinetic studies in 24 normal volunteers 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max Time-to-peak plasma concentration (min) 44 ± 34 33 ± 21 Mean value was simulated from observed plasma concentration data and standard deviation was simulated from percent coeffici
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1aae6a4d-0909-4672-aa26-e3f2d8c4d413 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Pharmacokinetic Parameters (units) Oral † Intramuscular* Intravenous Bolus ‡ 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b0aa1137-d0c3-4e4e-b1ec-5fe4b24e570a (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ar Derived from IM pharmacokinetic studies in 54 normal volunteers Intravenous Bolus Derived from IV pharmacokinetic studies in 24 normal volunteers 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max Time-to-peak plasma concentration (min) 44 ± 34 33 ± 21 Mean value was simulated from observed plasma concentration data and standard deviation was simulated from percent coeffici
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f0cd5dfa-7eba-449f-a54a-a5155024a77e (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Oral † Intramuscular* Intravenous Bolus ‡ Pharmacokinetic Parameters (units) 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:48245718-a2df-4938-8d06-3b8abf34181e (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ar Derived from IM pharmacokinetic studies in 54 normal volunteers Intravenous Bolus Derived from IV pharmacokinetic studies in 24 normal volunteers 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% Tmax Time to peak plasma concentration (min) 44 ± 34 33 ± 21 Mean value was simulated from observed plasma concentration data and standard deviation was simulated from percent coefficie
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:004588ba-e109-4a53-9c9d-a42dea9bb848 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Oral † Intramuscular* Intravenous Bolus ‡ Pharmacokinetic Parameters (units) 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2900e69d-29ec-210a-e063-6294a90a5008 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Oral † Intramuscular* Intravenous Bolus ‡ Pharmacokinetic Parameters (units) 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9fdba2e6-969f-4624-b08b-a42f99e4eff9 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ng Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Pharmacokinetic Parameters (units) Oral 1 Intramuscular 2 Intravenous Bolus 3 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 6 (min) 44 ± 34 33 ± 21 4 44 ± 29 33 ± 21 4 1.1 ± 0.7 4 2.9 ± 1.8 C max 7 (mcg/mL) [single-dose] 0.87 ± 0.22 1.14 ± 0.32 4 2.42 ± 0.68 4.55 ± 1.27 4 2.47 ± 0.51 4 4.65 ± 0.96 C ma
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5e42914f-de71-4176-819b-9fa26a8bdce6 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Pharmacokinetic Parameters (units) Oral † Intramuscular* Intravenous Bolus ‡ 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3b0aaf7f-c2fe-83c6-e063-6294a90a6f27 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        amuscular pharmacokinetic studies in 54 normal volunteers Intravenous Bolus Derived from intravenous pharmacokinetic studies in 24 normal volunteers 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max Time-to-peak plasma concentration (min) 44 ± 34 33 ± 21 Mean value was simulated from observed plasma concentration data and standard deviation was simulated from percent coeffici
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:23e7b5f7-ea0d-468d-9d13-a95f9bf605c6 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ar Derived from IM pharmacokinetic studies in 54 normal volunteers Intravenous Bolus Derived from IV pharmacokinetic studies in 24 normal volunteers 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max Time-to-peak plasma concentration (min) 44 ± 34 33 ± 21 Mean value was simulated from observed plasma concentration data and standard deviation was simulated from percent coeffici
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8accbb78-fc64-45d5-69b0-35c23a1d2a2e (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Oral † Intramuscular* Intravenous Bolus ‡ Pharmacokinetic Parameters (units) 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:22de8e1c-5e68-fd78-e063-6394a90ad40b (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Pharmacokinetic Parameters (units) Oral † Intramuscular* Intravenous Bolus ‡ 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max1(min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max2(mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max(mcg/mL) [steady state qid]
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2a23b0fa-803c-4abb-b588-12cfe83326a9 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Pharmacokinetic Parameters (units) Oral † Intramuscular* Intravenous Bolus ‡ 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ffd84ef3-26ed-4810-952b-4f0e913c5e32 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ar Derived from IM pharmacokinetic studies in 54 normal volunteers Intravenous Bolus Derived from IV pharmacokinetic studies in 24 normal volunteers 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max Time-to-peak plasma concentration (min) 44 ± 34 33 ± 21 Mean value was simulated from observed plasma concentration data and standard deviation was simulated from percent coeffici
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0c2c75c9-ed7b-46a8-9543-429bf2d8f090 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        owing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Pharmacokinetic Parameters (units) Oral* Intramuscular† Intravenous Bolus‡ 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44 ± 34 33 ± 21§ 44 ± 29 33 ± 21§ 1.1 ± 0.7§ 2.9 ± 1.8 C max 2 (mcg/mL) [single-dose] 0.87 ± 0.22 1.14 ± 0.32§ 2.42 ± 0.68 4.55 ± 1.27§ 2.47 ± 0.51§ 4.65 ± 0.96 C max (mcg
      52. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9e3ddc51-b572-8fe9-e053-2995a90a2f2a (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ng Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Oral † Intramuscular * Intravenous Bolus ‡ Pharmacokinetic Parameters (units) 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21 ** 44±29 33±21 ** 1.1±0.7 ** 2.9±1.8 C max 2 (mcg/mL) [single-dose] 0.87±0.22 1.14±0.32 ** 2.42±0.68 4.55±1.27 ** 2.47±0.51 ** 4.65±0.96 C max (mcg/mL) [steady
      53. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:29a92a7c-68d1-489b-ba27-d788b3153795 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ng Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Pharmacokinetic Parameters (units) Oral * Intramuscular † Intravenous Bolus ‡ 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44 ± 34 33 ± 21 § 44 ± 29 33 ± 21§ 1.1 ± 0.7 § 2.9 ± 1.8 C max 2 (mcg/mL) [single-dose] 0.87 ± 0.22 1.14 ± 0.32 § 2.42 ± 0.68 4.55 ± 1.27 § 2.47 ± 0.51 § 4.65 ± 0.96 C max
      54. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fe7eb195-48be-753b-e053-6294a90a8500 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ar Derived from IM pharmacokinetic studies in 54 normal volunteers Intravenous Bolus Derived from IV pharmacokinetic studies in 24 normal volunteers 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max Time-to-peak plasma concentration (min) 44 ± 34 33 ± 21 Mean value was simulated from observed plasma concentration data and standard deviation was simulated from percent coeffici
      55. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:42dfd39e-53a3-e9ee-e063-6394a90ab51e (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Pharmacokinetic Parameters (units) Oral † Intramuscular* Intravenous Bolus ‡ 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      56. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:08674066-7d4b-936d-e063-6394a90abbd7 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ar Derived from IM pharmacokinetic studies in 54 normal volunteers Intravenous Bolus Derived from IV pharmacokinetic studies in 24 normal volunteers 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% Tmax Time to peak plasma concentration (min) 44 ± 34 33 ± 21 Mean value was simulated from observed plasma concentration data and standard deviation was simulated from percent coefficie
      57. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d17ed469-677b-4a2e-96a9-5cfd0f50ecd9 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ng Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Pharmacokinetic Parameters (units) Oral 1 Intramuscular 2 Intravenous Bolus 3 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 6 (min) 44 ± 34 33 ± 21 4 44 ± 29 33 ± 21 4 1.1 ± 0.7 4 2.9 ± 1.8 C max 7 (mcg/mL) [single-dose] 0.87 ± 0.22 1.14 ± 0.32 4 2.42 ± 0.68 4.55 ± 1.27 4 2.47 ± 0.51 4 4.65 ± 0.96 C ma
      58. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3efb4f4e-b849-3bb5-e063-6394a90a5305 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Oral † Intramuscular* Intravenous Bolus ‡ Pharmacokinetic Parameters (units) 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      59. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2837a082-3a34-6f81-5e43-45a70295686b (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ar Derived from IM pharmacokinetic studies in 54 normal volunteers Intravenous Bolus Derived from IV pharmacokinetic studies in 24 normal volunteers 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max Time-to-peak plasma concentration (min) 44 ± 34 33 ± 21 Mean value was simulated from observed plasma concentration data and standard deviation was simulated from percent coeffici
      60. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:30a3ca20-8f98-478c-8a6b-aa617f0a17a3 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Oral † Intramuscular* Intravenous Bolus ‡ Pharmacokinetic Parameters (units) 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      61. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e0ed6947-5520-403b-bc0e-1caa95ab3302 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Pharmacokinetic Parameters (units) Oral † Intramuscular* Intravenous Bolus ‡ 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      62. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ada639d4-babb-2ad0-e053-2a95a90afce7 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Pharmacokinetic Parameters (units) Oral † Intramuscular* Intravenous Bolus ‡ 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      63. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e1fb8753-4695-4cb2-83d7-15d79fbaeeb2 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Pharmacokinetic Parameters (units) Oral* Intramuscular † Intravenous Bolus ‡ 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44 ± 34 33 ± 21§ 44 ± 29 33 ± 21§ 1.1 ± 0.7§ 2.9 ± 1.8 C max 2 (mcg/mL) [single-dose] 0.87 ± 0.22 1.14 ± 0.32§ 2.42 ± 0.68 4.55 ± 1.27§ 2.47 ± 0.51§ 4.65 ± 0.96 C max (mcg
      64. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1e8ddf13-c513-4e16-a91a-9d55726d9071 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        le dose ** Mean value was simulated from observed plasma concentration data and standard deviation was simulated from percent coefficient of variation for observed C max and T max data Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      65. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:62591551-a644-4b2c-a0de-982e906fabc3 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        from percent coefficient of variation for observed C max and T max data Pharmacokinetic Parameters (units) Oral † Intramuscular* Intravenous Bolus ‡ 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      66. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4596483b-990b-eaa4-e063-6394a90ac08f (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Pharmacokinetic Parameters (units) Oral † Intramuscular* Intravenous Bolus ‡ 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21 ** 44±29 33±21 ** 1.1±0.7 ** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87± 0.22 1.14± 0.32** 2.42±0.68 4.55±1.27 ** 2.47± 0.51 ** 4.65± 0.96 C max (mcg/mL) [ste
      67. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f520978f-9046-4ff8-b04d-0f615fdeae4d (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Oral † Intramuscular* Intravenous Bolus ‡ Pharmacokinetic Parameters (units) 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% Tmax 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      68. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:36713fb3-d301-432d-a95d-06e368fc8a22 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ar Derived from IM pharmacokinetic studies in 54 normal volunteers Intravenous Bolus Derived from IV pharmacokinetic studies in 24 normal volunteers 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% Tmax Time to peak plasma concentration (min) 44 ± 34 33 ± 21 Mean value was simulated from observed plasma concentration data and standard deviation was simulated from percent coefficie
      69. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c1717245-cef3-b3d7-e053-2a95a90a1ac5 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        owing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Pharmacokinetic Parameters (units) Oral1 Intramuscular2 Intravenous Bolus3 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% Tmax6 (min) 44 ± 34 33 ± 214 44 ± 29 33 ± 214 1.1 ± 0.74 2.9 ± 1.8 Cmax7 (mcg/mL) [single-dose] 0.87 ± 0.22 1.14 ± 0.324 2.42 ± 0.68 4.55 ± 1.274 2.47 ± 0.514 4.65 ± 0.96 Cmax (mcg/mL)
      70. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:014ba8d7-7ed3-4d4a-847a-22b65161117e (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        from percent coefficient of variation for observed C max and T max data Pharmacokinetic Parameters (units) Oral † Intramuscular* Intravenous Bolus ‡ 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      71. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9e5fde54-2206-4072-afb8-4d06a8d314b1 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ar Derived from IM pharmacokinetic studies in 54 normal volunteers Intravenous Bolus Derived from IV pharmacokinetic studies in 24 normal volunteers 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% Tmax 6 (min) 44 ± 34 33 ± 21 Mean value was simulated from observed plasma concentration data and standard deviation was simulated from percent coefficient of variation for observed Cma
      72. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:588b4804-4ac5-4b96-947e-354029ea4df9 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Oral † Intramuscular* Intravenous Bolus ‡ Pharmacokinetic Parameters (units) 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      73. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bdfb7f14-ad9c-4901-844b-aacfbb4429c3 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Oral † Intramuscular* Intravenous Bolus ‡ Pharmacokinetic Parameters (units) 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      74. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:04d5114e-332b-4ed0-85df-b276c1dc296c (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        amuscular pharmacokinetic studies in 54 normal volunteers Intravenous Bolus Derived from intravenous pharmacokinetic studies in 24 normal volunteers 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max Time-to-peak plasma concentration (min) 44 ± 34 33 ± 21 Mean value was simulated from observed plasma concentration data and standard deviation was simulated from percent coeffici
      75. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3d88cbe6-5230-47aa-80af-0c41283d1f00 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        from percent coefficient of variation for observed C max and T max data Oral † Intramuscular* Intravenous Bolus ‡ Pharmacokinetic Parameters (units) 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      76. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f47d4365-40a8-445b-99cd-49edad6a8ffc (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ng Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Pharmacokinetic Parameters (units) Oral 1 Intramuscular 2 Intravenous Bolus 3 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 6 (min) 44 ± 34 33 ± 21 4 44 ± 29 33 ± 21 4 1.1 ± 0.7 4 2.9 ± 1.8 C max 7 (mcg/mL) [single-dose] 0.87 ± 0.22 1.14 ± 0.32 4 2.42 ± 0.68 4.55 ± 1.27 4 2.47 ± 0.51 4 4.65 ± 0.96 C ma
      77. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dd489c86-08c0-4457-86f3-c4f36a70276c (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Oral † Intramuscular* Intravenous Bolus ‡ Pharmacokinetic Parameters (units) 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      78. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:19fffe42-a02d-26eb-e063-6294a90aea5a (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        concentration À Average plasma concentration È Volume of distribution Pharmacokinetic Parameters (units) Oral * Intramuscular † Intravenous Bolus ‡ 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max§ (min) 44 ± 34 33 ± 21 ¶ 44 ± 29 33 ± 21 ¶ 1.1 ± 0.7 ¶ 2.9 ± 1.8 C max# (mcg/mL) [single-dose] 0.87 ± 0.22 1.14 ± 0.32 ¶ 2.42 ± 0.68 4.55 ± 1.27 ¶ 2.47 ± 0.51 ¶ 4.65 ± 0.96 C max
      79. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4b58836d-9d58-4539-9691-9e11c505ef2a (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Oral † Intramuscular* Intravenous Bolus ‡ Pharmacokinetic Parameters (units) 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      80. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:478aff0b-29fd-43b2-a701-5236b8f8e3df (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Oral † Intramuscular* Intravenous Bolus ǂ Pharmacokinetic Parameters (units) 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      81. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:950b7295-3f68-4027-ac2b-2f7d0f5f8ef9 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        from percent coefficient of variation for observed C max and T max data Oral † Intramuscular* Intravenous Bolus ‡ Pharmacokinetic Parameters (units) 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      82. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:155c9171-d394-9c28-e063-6394a90a8209 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ar Derived from IM pharmacokinetic studies in 54 normal volunteers Intravenous Bolus Derived from IV pharmacokinetic studies in 24 normal volunteers 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max Time-to-peak plasma concentration (min) 44 ± 34 33 ± 21 Mean value was simulated from observed plasma concentration data and standard deviation was simulated from percent coeffici
      83. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:94c7c57a-fd1e-41ab-bc39-9a538f6011d1 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ng Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Pharmacokinetic Parameters (units) Oral 1 Intramuscular 2 Intravenous Bolus 3 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max6 (min) 44 ± 34 33 ± 21 4 44 ± 29 33 ± 21 4 1.1 ± 0.7 4 2.9 ± 1.8 C max7 (mcg/mL) [single-dose] 0.87 ± 0.22 1.14 ± 0.32 4 2.42 ± 0.68 4.55 ± 1.27 4 2.47 ± 0.51 4 4.65 ± 0.96 C max
      84. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:afc691f8-517a-4d88-8322-87dafec8f064 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ar Derived from IM pharmacokinetic studies in 54 normal volunteers Intravenous Bolus Derived from IV pharmacokinetic studies in 24 normal volunteers 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% Tmax Time to peak plasma concentration (min) 44 ± 34 33 ± 21 Mean value was simulated from observed plasma concentration data and standard deviation was simulated from percent coefficie
      85. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:18b450d2-e715-4710-a1d8-22b782f87f9c (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ar Derived from IM pharmacokinetic studies in 54 normal volunteers Intravenous Bolus Derived from IV pharmacokinetic studies in 24 normal volunteers 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% Tmax Time to peak plasma concentration (min) 44 ± 34 33 ± 21 Mean value was simulated from observed plasma concentration data and standard deviation was simulated from percent coefficie
      86. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:38fc11a0-50d1-4ba5-8d46-331eb74a00d6 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        amuscular pharmacokinetic studies in 54 normal volunteers Intravenous Bolus Derived from intravenous pharmacokinetic studies in 24 normal volunteers 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max Time-to-peak plasma concentration (min) 44 ± 34 33 ± 21 Mean value was simulated from observed plasma concentration data and standard deviation was simulated from percent coeffici
      87. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:49e04373-568d-48fa-ac1c-b7d6b493e777 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Pharmacokinetic Parameters (units) Oral* Intramuscular † Intravenous Bolus ‡ 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44 ± 34 33 ± 21§ 44 ± 29 33 ± 21§ 1.1 ± 0.7§ 2.9 ± 1.8 C max 2 (mcg/mL) [single-dose] 0.87 ± 0.22 1.14 ± 0.32§ 2.42 ± 0.68 4.55 ± 1.27§ 2.47 ± 0.51§ 4.65 ± 0.96 C max (mcg
      88. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d8e928ac-c1e7-4b7a-87cd-9d11e36d53c0 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ar Derived from IM pharmacokinetic studies in 54 normal volunteers Intravenous Bolus Derived from IV pharmacokinetic studies in 24 normal volunteers 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max Time-to-peak plasma concentration (min) 44 ± 34 33 ± 21 Mean value was simulated from observed plasma concentration data and standard deviation was simulated from percent coeffici
      89. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ce992bee-a9f5-48bd-a00e-513f590d69f2 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        wing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Oral† Intramuscular* Intravenous Bolus ‡ Pharmacokinetic Parameters (units) 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      90. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:43d07956-90ba-4e96-b265-aec03eced19b (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Pharmacokinetic Parameters (units) Oral † Intramuscular* Intravenous Bolus ‡ 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      91. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:337afb4f-789f-4cac-817a-e4286664a71e (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        amuscular pharmacokinetic studies in 54 normal volunteers Intravenous Bolus Derived from intravenous pharmacokinetic studies in 24 normal volunteers 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max Time-to-peak plasma concentration (min) 44 ± 34 33 ± 21 Mean value was simulated from observed plasma concentration data and standard deviation was simulated from percent coeffici
      92. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2d552135-bde5-5fe9-e063-6394a90af433 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        amuscular pharmacokinetic studies in 54 normal volunteers Intravenous Bolus Derived from intravenous pharmacokinetic studies in 24 normal volunteers 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max Time-to-peak plasma concentration (min) 44 ± 34 33 ± 21 Mean value was simulated from observed plasma concentration data and standard deviation was simulated from percent coeffici
      93. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:46434a32-b727-0c5b-e063-6394a90a0c48 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Oral † Intramuscular* Intravenous Bolus ‡ Pharmacokinetic Parameters (units) 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      94. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b574ccc9-936c-4877-bd65-7f58f741b5e6 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Pharmacokinetic Parameters (units) Oral † Intramuscular* Intravenous Bolus ‡ 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      95. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e17f583d-8bd4-3ed0-e053-2a95a90a9090 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Pharmacokinetic Parameters (units) Oral † Intramuscular* Intravenous Bolus ‡ 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      96. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:57ea681c-392e-4f41-a374-91ed20473161 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ar Derived from IM pharmacokinetic studies in 54 normal volunteers Intravenous Bolus Derived from IV pharmacokinetic studies in 24 normal volunteers 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max Time-to-peak plasma concentration (min) 44 ± 34 33 ± 21 Mean value was simulated from observed plasma concentration data and standard deviation was simulated from percent coeffici
      97. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:415a5393-296f-30e3-e054-00144ff8d46c (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ar Derived from IM pharmacokinetic studies in 54 normal volunteers Intravenous Bolus Derived from IV pharmacokinetic studies in 24 normal volunteers 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max Time-to-peak plasma concentration (min) 44 ± 34 33 ± 21 Mean value was simulated from observed plasma concentration data and standard deviation was simulated from percent coeffici
      98. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:419cf756-3c96-4bb8-ae96-6aea5a5f3afd (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Oral † Intramuscular* Intravenous Bolus ‡ Pharmacokinetic Parameters (units) 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      99. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:275f9131-5915-a585-e063-6294a90ab0fc (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Pharmacokinetic Parameters (units) Oral † Intramuscular* Intravenous Bolus ‡ 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      100. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:eda4b884-527c-42d3-971b-4d1678e5adbf (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        amuscular pharmacokinetic studies in 54 normal volunteers Intravenous Bolus Derived from intravenous pharmacokinetic studies in 24 normal volunteers 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max Time-to-peak plasma concentration (min) 44 ± 34 33 ± 21 Mean value was simulated from observed plasma concentration data and standard deviation was simulated from percent coeffici
      101. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0952d430-2665-4952-ba06-ab99f054f4df (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ar Derived from IM pharmacokinetic studies in 54 normal volunteers Intravenous Bolus Derived from IV pharmacokinetic studies in 24 normal volunteers 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% Tmax Time to peak plasma concentration (min) 44 ± 34 33 ± 21 Mean value was simulated from observed plasma concentration data and standard deviation was simulated from percent coefficie
      102. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6f727e1f-2838-427b-a236-eeb0101b08f3 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        from percent coefficient of variation for observed C max and T max data Pharmacokinetic Parameters (units) Oral † Intramuscular* Intravenous Bolus ‡ 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      103. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:63b73913-246d-4e5b-bdc9-c202980d8777 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ing Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Oral † Intramuscular* Intravenous Bolus ‡ Pharmacokinetic Parameters (units) 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      104. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:37453bcd-e34b-5902-e063-6294a90a0245 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ar Derived from IM pharmacokinetic studies in 54 normal volunteers Intravenous Bolus Derived from IV pharmacokinetic studies in 24 normal volunteers 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% Tmax Time to peak plasma concentration (min) 44 ± 34 33 ± 21 Mean value was simulated from observed plasma concentration data and standard deviation was simulated from percent coefficie
      105. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d1920335-8e45-4960-b6e9-e6f1f9e6820c (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        from percent coefficient of variation for observed C max and T max data Oral † Intramuscular* Intravenous Bolus ‡ Pharmacokinetic Parameters (units) 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8 C max 2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96 C max (mcg/mL) [steady state
      106. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5a4192e8-d9e5-4f09-99f6-da5a648b1aac (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ar Derived from IM pharmacokinetic studies in 54 normal volunteers Intravenous Bolus Derived from IV pharmacokinetic studies in 24 normal volunteers 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max Time-to-peak plasma concentration (min) 44 ± 34 33 ± 21 Mean value was simulated from observed plasma concentration data and standard deviation was simulated from percent coeffici
      107. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:add10ccd-c205-4512-9619-253290fa1152 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ng Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine Pharmacokinetic Parameters (units) Oral 1 Intramuscular 2 Intravenous Bolus 3 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max 6 (min) 44 ± 34 33 ± 21 4 44 ± 29 33 ± 21 4 1.1 ± 0.7 4 2.9 ± 1.8 C max 7 (mcg/mL) [single-dose] 0.87 ± 0.22 1.14 ± 0.32 4 2.42 ± 0.68 4.55 ± 1.27 4 2.47 ± 0.51 4 4.65 ± 0.96 C ma
      108. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1e7ae5af-76b9-49a9-ba14-52b566929c22 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        ar Derived from IM pharmacokinetic studies in 54 normal volunteers Intravenous Bolus Derived from IV pharmacokinetic studies in 24 normal volunteers 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg Bioavailability (extent) 100% T max Time-to-peak plasma concentration (min) 44 ± 34 33 ± 21 Mean value was simulated from observed plasma concentration data and standard deviation was simulated from percent coeffici

  6. Projected row 806

    Medicine slug
    ketorolac
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    146
    Source count
    118
    Agreement rate
    1
    Recorded readings

    1. 2.5 hours

      Numeric value
      2.5
      Unit
      hours
      Source records
      118

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 118 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e0065781-ea33-4662-a8b1-c936e937ac9f (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:46dc8f62-e754-50e3-e054-00144ff8d46c (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:688f5dec-a6db-43c6-a1f8-5df99d08d395 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f4e7f1c8-e458-0860-e053-2a95a90a1bf0 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8f36fde8-bc59-4a59-8659-b173cfd15774 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:606b0f2f-de28-42a9-96f4-cacba2c7c56a (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:99c06dde-f218-4d81-91e0-f37a748872d6 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:862dd7b7-8ed5-42bf-870e-a45b86740226 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3f2956d9-9e68-f35e-e063-6394a90a706d (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2301a6a2-b88a-4c0d-bb6c-ad4a8af7da39 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:26a1761b-90bf-49c6-9e6a-f293af2296ce (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f335a030-ffa8-4f42-8166-2f06e036b40d (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e46ebc7f-584e-e2b7-e053-2995a90ad17b (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD±0.4) compared with 5 hours (SD±1.7) for the R-enantiomer.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8b26240c-b72b-42a6-ab33-a1e38224fbe0 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3855f527-fd6c-4f24-a4b4-cd47eec1193d (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6fa20b41-f860-4fea-b1fb-ab6d3fa34a90 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ee44c322-4b4b-4397-a1a5-e5b3c3c5a053 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b88e562d-226b-4200-afa5-034e628c660f (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD±0.4) compared with 5 hours (SD±1.7) for the R-enantiomer.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f5170993-81a9-4eb7-95ac-60697a5ee1d7 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f713500a-20b8-8e20-c4cc-956805170335 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:18981677-8049-4864-b31c-96a299e3194d (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ccf905ca-e164-4779-9485-2d139c821bad (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R- enantiomer.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:48244614-53ec-47e6-ad48-50814bdcceb7 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6758cb38-dec8-468f-94e2-613772e39b9a (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54dec321-b4c9-f0d6-e063-6294a90ae231 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5734e81e-2471-1314-e063-6294a90ac9fe (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0749f61d-12e6-4280-8f41-bd4df81e7ae6 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ec6d453b-4b84-53d4-e053-2995a90a6006 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:10827042-a2d4-44f9-837d-2023a3d552ff (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:04df9620-6dcb-494a-83e2-6d28036be974 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5abd4389-4fb2-408b-a27e-cf64b6a921f1 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:29003279-8f27-bcdc-e063-6394a90aa639 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2cf7516b-ac86-ca72-e063-6394a90a4339 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD± 0.4) compared with 5 hours (SD±1.7) for the R-enantiomer.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cdd4d548-33f8-42d6-8eae-e36aa577c050 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3321b610-1c9b-4314-adbb-a2e163234dec (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:45966992-5af6-bf10-e063-6294a90af25b (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:49dd153c-10e8-505b-e063-6394a90a595f (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:32198544-4a46-495c-ab65-0836dcbc2c49 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:51d443f8-716d-af3a-e063-6394a90a56a3 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1aae6a4d-0909-4672-aa26-e3f2d8c4d413 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b0aa1137-d0c3-4e4e-b1ec-5fe4b24e570a (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f0cd5dfa-7eba-449f-a54a-a5155024a77e (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:48245718-a2df-4938-8d06-3b8abf34181e (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:004588ba-e109-4a53-9c9d-a42dea9bb848 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:97005a1c-167e-4676-bae7-e49b38c36f9e (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2900e69d-29ec-210a-e063-6294a90a5008 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9fdba2e6-969f-4624-b08b-a42f99e4eff9 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5e42914f-de71-4176-819b-9fa26a8bdce6 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3b0aaf7f-c2fe-83c6-e063-6294a90a6f27 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:23e7b5f7-ea0d-468d-9d13-a95f9bf605c6 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8accbb78-fc64-45d5-69b0-35c23a1d2a2e (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      52. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:22de8e1c-5e68-fd78-e063-6394a90ad40b (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      53. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2a23b0fa-803c-4abb-b588-12cfe83326a9 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      54. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ffd84ef3-26ed-4810-952b-4f0e913c5e32 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      55. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0c2c75c9-ed7b-46a8-9543-429bf2d8f090 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      56. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9e3ddc51-b572-8fe9-e053-2995a90a2f2a (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD±0.4) compared with 5 hours (SD±1.7) for the R-enantiomer.
      57. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:29a92a7c-68d1-489b-ba27-d788b3153795 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      58. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fe7eb195-48be-753b-e053-6294a90a8500 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      59. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:42dfd39e-53a3-e9ee-e063-6394a90ab51e (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      60. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:08674066-7d4b-936d-e063-6394a90abbd7 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      61. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d17ed469-677b-4a2e-96a9-5cfd0f50ecd9 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      62. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3efb4f4e-b849-3bb5-e063-6394a90a5305 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      63. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:515464a7-16c5-2811-e063-6294a90aa451 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      64. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2837a082-3a34-6f81-5e43-45a70295686b (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      65. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:30a3ca20-8f98-478c-8a6b-aa617f0a17a3 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      66. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e0ed6947-5520-403b-bc0e-1caa95ab3302 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      67. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ada639d4-babb-2ad0-e053-2a95a90afce7 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      68. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e1fb8753-4695-4cb2-83d7-15d79fbaeeb2 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD± 0.4) compared with 5 hours (SD±1.7) for the R-enantiomer.
      69. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1e8ddf13-c513-4e16-a91a-9d55726d9071 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      70. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:62591551-a644-4b2c-a0de-982e906fabc3 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      71. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4596483b-990b-eaa4-e063-6394a90ac08f (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      72. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f520978f-9046-4ff8-b04d-0f615fdeae4d (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      73. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:36713fb3-d301-432d-a95d-06e368fc8a22 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      74. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c1717245-cef3-b3d7-e053-2a95a90a1ac5 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      75. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:014ba8d7-7ed3-4d4a-847a-22b65161117e (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD±0.4) compared with 5 hours (SD±1.7) for the R-enantiomer.
      76. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9e5fde54-2206-4072-afb8-4d06a8d314b1 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      77. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:76446045-3cca-0206-e053-2a91aa0a2440 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      78. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:588b4804-4ac5-4b96-947e-354029ea4df9 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      79. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bdfb7f14-ad9c-4901-844b-aacfbb4429c3 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      80. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1e65d11b-5aa9-4a6b-b5d6-c19828748fea (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      81. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3d746288-681a-5232-e063-6394a90afabd (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      82. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:04d5114e-332b-4ed0-85df-b276c1dc296c (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      83. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3d88cbe6-5230-47aa-80af-0c41283d1f00 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      84. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ae6c60c0-e88a-45b2-e053-2995a90ac62f (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      85. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f47d4365-40a8-445b-99cd-49edad6a8ffc (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      86. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dd489c86-08c0-4457-86f3-c4f36a70276c (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      87. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:19fffe42-a02d-26eb-e063-6294a90aea5a (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      88. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4b58836d-9d58-4539-9691-9e11c505ef2a (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      89. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:478aff0b-29fd-43b2-a701-5236b8f8e3df (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      90. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:950b7295-3f68-4027-ac2b-2f7d0f5f8ef9 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      91. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:155c9171-d394-9c28-e063-6394a90a8209 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      92. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:94c7c57a-fd1e-41ab-bc39-9a538f6011d1 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      93. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:afc691f8-517a-4d88-8322-87dafec8f064 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      94. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:18b450d2-e715-4710-a1d8-22b782f87f9c (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      95. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:38fc11a0-50d1-4ba5-8d46-331eb74a00d6 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      96. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:49e04373-568d-48fa-ac1c-b7d6b493e777 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD± 0.4) compared with 5 hours (SD±1.7) for the R-enantiomer.
      97. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d8e928ac-c1e7-4b7a-87cd-9d11e36d53c0 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      98. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ce992bee-a9f5-48bd-a00e-513f590d69f2 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      99. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:43d07956-90ba-4e96-b265-aec03eced19b (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      100. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:337afb4f-789f-4cac-817a-e4286664a71e (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      101. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:521b3d09-df08-fcae-e063-6294a90a6545 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      102. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2d552135-bde5-5fe9-e063-6394a90af433 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      103. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:46434a32-b727-0c5b-e063-6394a90a0c48 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      104. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b574ccc9-936c-4877-bd65-7f58f741b5e6 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      105. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e17f583d-8bd4-3ed0-e053-2a95a90a9090 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      106. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:57ea681c-392e-4f41-a374-91ed20473161 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      107. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:415a5393-296f-30e3-e054-00144ff8d46c (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      108. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:419cf756-3c96-4bb8-ae96-6aea5a5f3afd (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      109. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:275f9131-5915-a585-e063-6294a90ab0fc (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      110. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:eda4b884-527c-42d3-971b-4d1678e5adbf (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      111. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0952d430-2665-4952-ba06-ab99f054f4df (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      112. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6f727e1f-2838-427b-a236-eeb0101b08f3 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      113. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:63b73913-246d-4e5b-bdc9-c202980d8777 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      114. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:37453bcd-e34b-5902-e063-6294a90a0245 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      115. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d1920335-8e45-4960-b6e9-e6f1f9e6820c (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      116. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5a4192e8-d9e5-4f09-99f6-da5a648b1aac (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      117. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:add10ccd-c205-4512-9619-253290fa1152 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.
      118. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1e7ae5af-76b9-49a9-ba14-52b566929c22 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer.

  7. Projected row 807

    Medicine slug
    ketorolac
    Compared field
    tMax
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    146
    Source count
    54
    Agreement rate
    1
    Recorded readings

    1. 1 hour

      Numeric value
      1
      Unit
      hours
      Source records
      54

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 54 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:46dc8f62-e754-50e3-e054-00144ff8d46c (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:688f5dec-a6db-43c6-a1f8-5df99d08d395 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f4e7f1c8-e458-0860-e053-2a95a90a1bf0 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8f36fde8-bc59-4a59-8659-b173cfd15774 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:862dd7b7-8ed5-42bf-870e-a45b86740226 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8b26240c-b72b-42a6-ab33-a1e38224fbe0 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3855f527-fd6c-4f24-a4b4-cd47eec1193d (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1hour.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6fa20b41-f860-4fea-b1fb-ab6d3fa34a90 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f5170993-81a9-4eb7-95ac-60697a5ee1d7 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f713500a-20b8-8e20-c4cc-956805170335 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:18981677-8049-4864-b31c-96a299e3194d (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:48244614-53ec-47e6-ad48-50814bdcceb7 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5734e81e-2471-1314-e063-6294a90ac9fe (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0749f61d-12e6-4280-8f41-bd4df81e7ae6 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ec6d453b-4b84-53d4-e053-2995a90a6006 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:10827042-a2d4-44f9-837d-2023a3d552ff (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:04df9620-6dcb-494a-83e2-6d28036be974 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2cf7516b-ac86-ca72-e063-6394a90a4339 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine tablets after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:51d443f8-716d-af3a-e063-6394a90a56a3 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b0aa1137-d0c3-4e4e-b1ec-5fe4b24e570a (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:48245718-a2df-4938-8d06-3b8abf34181e (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9fdba2e6-969f-4624-b08b-a42f99e4eff9 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3b0aaf7f-c2fe-83c6-e063-6294a90a6f27 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:23e7b5f7-ea0d-468d-9d13-a95f9bf605c6 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ffd84ef3-26ed-4810-952b-4f0e913c5e32 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fe7eb195-48be-753b-e053-6294a90a8500 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:08674066-7d4b-936d-e063-6394a90abbd7 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d17ed469-677b-4a2e-96a9-5cfd0f50ecd9 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:515464a7-16c5-2811-e063-6294a90aa451 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e1fb8753-4695-4cb2-83d7-15d79fbaeeb2 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine tablets after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:36713fb3-d301-432d-a95d-06e368fc8a22 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c1717245-cef3-b3d7-e053-2a95a90a1ac5 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9e5fde54-2206-4072-afb8-4d06a8d314b1 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:04d5114e-332b-4ed0-85df-b276c1dc296c (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f47d4365-40a8-445b-99cd-49edad6a8ffc (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:19fffe42-a02d-26eb-e063-6294a90aea5a (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:155c9171-d394-9c28-e063-6394a90a8209 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:94c7c57a-fd1e-41ab-bc39-9a538f6011d1 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:afc691f8-517a-4d88-8322-87dafec8f064 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:18b450d2-e715-4710-a1d8-22b782f87f9c (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:38fc11a0-50d1-4ba5-8d46-331eb74a00d6 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:49e04373-568d-48fa-ac1c-b7d6b493e777 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine tablets after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d8e928ac-c1e7-4b7a-87cd-9d11e36d53c0 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:337afb4f-789f-4cac-817a-e4286664a71e (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:521b3d09-df08-fcae-e063-6294a90a6545 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2d552135-bde5-5fe9-e063-6394a90af433 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:57ea681c-392e-4f41-a374-91ed20473161 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:415a5393-296f-30e3-e054-00144ff8d46c (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:eda4b884-527c-42d3-971b-4d1678e5adbf (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0952d430-2665-4952-ba06-ab99f054f4df (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:37453bcd-e34b-5902-e063-6294a90a0245 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      52. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5a4192e8-d9e5-4f09-99f6-da5a648b1aac (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      53. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:add10ccd-c205-4512-9619-253290fa1152 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.
      54. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1e7ae5af-76b9-49a9-ba14-52b566929c22 (opens source in a new tab)

        Ketorolac label

        Version not recorded · Effective date not recorded

        Oral administration of ketorolac tromethamine after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour.

  8. Projected row 808

    Medicine slug
    labetalol
    Compared field
    bioavailability
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    87
    Source count
    57
    Agreement rate
    1
    Recorded readings

    1. 100%

      Numeric value
      100
      Unit
      %
      Source records
      57

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 57 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed0188ba-3fd3-4680-a829-ba242a115fab (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol hydrochloride compared to an oral solution is 100%.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e6836a01-220d-4b69-9b4a-c919daeb6ece (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol hydrochloride compared to an oral solution is 100%.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54b75509-824b-4291-818d-71dc1b88915f (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol HCl tablets compared to an oral solution is 100%.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:30281c4d-2fd1-167a-e063-6294a90a77c4 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol HCl tablets compared to an oral solution is 100%.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:35b5fd32-581d-427b-9a13-b7a02846d21d (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol HCl tablets compared to an oral solution is 100%.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c586ab65-56e8-4a4f-b471-902198d3e58c (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol hydrochloride compared to an oral solution is 100%.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f1f28e7a-048c-436b-8901-7072ac1d81b7 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol HCl tablets compared to an oral solution is 100%.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d80f884d-2092-4ddc-9e5a-5cce2974d61c (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol HCl tablets compared to an oral solution is 100%.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:06ff81fe-9226-49a7-aa5c-f52b059d7cab (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol HCl tablets compared to an oral solution is 100%.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:312dde0d-5147-483e-968f-4e0d46114176 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol HCl tablets compared to an oral solution is 100%.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0dcd514d-bda8-484b-8cf1-f5656aaab9ce (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol hydrochloride compared to an oral solution is 100%.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5bd81a8a-a480-4c8d-bd4f-3158412e6a73 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol hydrochloride compared to an oral solution is 100%.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5101b8dd-6148-465c-9bba-0209ce823fe5 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol HCl tablets compared to an oral solution is 100%.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5954cc5c-3e73-e039-e063-6394a90a7d6a (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol hydrochloride compared to an oral solution is 100%.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:28c91727-e5a8-48b3-a4df-d7bec8feda40 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol hydrochloride compared to an oral solution is 100%.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5a39bb96-4a60-49e8-859c-16bda0fe18e4 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol hydrochloride compared to an oral solution is 100%.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:20c26652-52da-4eef-8486-f91eb30e9ff7 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol hydrochloride compared to an oral solution is 100%.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:faf7a1ff-f18a-8ca7-e053-6394a90a1b1f (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol HCl tablets compared to an oral solution is 100%.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:106a0959-5830-489f-ba60-afd4eb0fac36 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol hydrochloride compared to an oral solution is 100%.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c0c1a162-cd30-4ac9-bc62-407493ed54a5 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol HCl tablets compared to an oral solution is 100%.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1c680447-b43a-4ff1-bc64-2c2174ca1c9a (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol hydrochloride compared to an oral solution is 100%.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1e1b7355-4802-d277-e063-6394a90aef44 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol HCl tablets compared to an oral solution is 100%.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1a71964e-e6fa-443e-bfdd-f8852f8cf29e (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol hydrochloride compared to an oral solution is 100%.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:94abdd54-a8e2-4858-8183-6c5d04dbceb5 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol hydrochloride compared to an oral solution is 100%.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a007d945-417c-4647-ab03-95ca219d7d38 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol HCl tablets compared to an oral solution is 100%.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5fba93fc-4580-48c2-a1ec-5d446680adcf (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol hydrochloride compared to an oral solution is 100%.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5faacbcc-f88f-42f7-8702-791ee82c4d18 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol hydrochloride compared to an oral solution is 100%.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:27e4ab03-c17b-4268-912c-e45a5e8f8dd8 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol HCl tablets compared to an oral solution is 100%.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ae5d7b3b-e444-48d3-9d85-9b07319f9374 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol hydrochloride compared to an oral solution is 100%.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e4562c70-f245-4dbe-8fe1-0bb64a91a315 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol hydrochloride compared to an oral solution is 100%.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d207396a-068e-4229-88cc-a1a4df7aeff2 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol HCl tablets compared to an oral solution is 100%.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c0301841-e209-4242-bace-58a20e6dd01b (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol HCl tablets compared to an oral solution is 100%.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:706a877b-c388-43e7-b083-518111b288b0 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol hydrochloride compared to an oral solution is 100%.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:143ae21e-c350-4c92-b318-7537f4e46596 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol hydrochloride compared to an oral solution is 100%.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:64cd636d-8b48-4f29-b41d-4a048335793e (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol hydrochloride compared to an oral solution is 100%.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bf84ebae-3c91-4448-b1db-8e5ed3053866 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol hydrochloride compared to an oral solution is 100%.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f9af85d3-a5a7-49d6-aff6-1ca2b2d75450 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol HCl tablets compared to an oral solution is 100%.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0db22a64-1863-4188-850b-273ea746e327 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol hydrochloride compared to an oral solution is 100%.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:83a6e770-207a-46bc-992d-c1ad90d1006d (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol HCl tablets compared to an oral solution is 100%.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3aff731f-1eec-19b5-e063-6294a90a3143 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol HCl tablets compared to an oral solution is 100%.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e2e50571-d8c1-43e7-b90f-877ba1c35c9b (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol hydrochloride compared to an oral solution is 100%.
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:04f9dcdf-4023-48ee-9e7d-ca9366d9db72 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol hydrochloride compared to an oral solution is 100%.
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a5b65a9b-6b8a-48a4-9c72-0e605bb309eb (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol HCl tablets compared to an oral solution is 100%.
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6f919513-500e-4a05-935e-b6fc1615368a (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol hydrochloride compared to an oral solution is 100%.
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:371cb135-6a5f-433d-a87d-ab8521c4aa6d (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol HCl tablets compared to an oral solution is 100%.
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d3ca153c-25b2-4506-91bd-bf9d6a4c01fe (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol HCl tablets compared to an oral solution is 100%.
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed2293f8-2b82-c3db-e053-2995a90ad46c (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol hydrochloride compared to an oral solution is 100%.
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fffb7c59-ad92-4e74-850d-d94d42b7fdc9 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol hydrochloride compared to an oral solution is 100%.
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b950655d-a9f8-4ace-bb56-0c7abbca231e (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol hydrochloride compared to an oral solution is 100%.
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b4a5f170-a400-4986-8c64-f55d0413f0f6 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol HCl tablets compared to an oral solution is 100%.
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dafa7411-2857-4f5a-a587-4367cfbe2bfa (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol HCl tablets compared to an oral solution is 100%.
      52. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:32525ed4-3cca-2b99-e063-6294a90a6c66 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol hydrochloride compared to an oral solution is 100%.
      53. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d4364caf-46c6-4144-9ba5-2c561e4f3a95 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol HCl tablets compared to an oral solution is 100%.
      54. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d5ce687f-4a37-d3e6-e053-2995a90aa974 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol HCl tablets compared to an oral solution is 100%.
      55. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:63ede355-42ec-4c52-a941-51e5f6b35ed6 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol hydrochloride compared to an oral solution is 100%.
      56. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1fce27dd-90a6-45cf-9bd7-13147d3cc0d7 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol hydrochloride compared to an oral solution is 100%.
      57. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:30280d40-28df-4c88-93bd-357a7c528906 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The relative bioavailability of labetalol HCl tablets compared to an oral solution is 100%.

  9. Projected row 809

    Medicine slug
    labetalol
    Compared field
    halfLife
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    87
    Source count
    86
    Agreement rate
    0.77907
    Recorded readings

    1. 6 to 8 hours

      Numeric value
      6
      Unit
      hours
      Source records
      67

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 67 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed0188ba-3fd3-4680-a829-ba242a115fab (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e6836a01-220d-4b69-9b4a-c919daeb6ece (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:82fc2d64-0572-4a9b-94fc-f6eb8d930c54 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        Elimination The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54b75509-824b-4291-818d-71dc1b88915f (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:30281c4d-2fd1-167a-e063-6294a90a77c4 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:35b5fd32-581d-427b-9a13-b7a02846d21d (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c586ab65-56e8-4a4f-b471-902198d3e58c (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f1f28e7a-048c-436b-8901-7072ac1d81b7 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d80f884d-2092-4ddc-9e5a-5cce2974d61c (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:06ff81fe-9226-49a7-aa5c-f52b059d7cab (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:312dde0d-5147-483e-968f-4e0d46114176 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0dcd514d-bda8-484b-8cf1-f5656aaab9ce (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5bd81a8a-a480-4c8d-bd4f-3158412e6a73 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5101b8dd-6148-465c-9bba-0209ce823fe5 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5954cc5c-3e73-e039-e063-6394a90a7d6a (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f7f7fade-98a6-4741-bfb9-f1eb54ad4565 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        Elimination The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:28c91727-e5a8-48b3-a4df-d7bec8feda40 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:63db5b00-e864-4b2d-84f2-00bf35211b9b (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5a39bb96-4a60-49e8-859c-16bda0fe18e4 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:20c26652-52da-4eef-8486-f91eb30e9ff7 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:faf7a1ff-f18a-8ca7-e053-6394a90a1b1f (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:106a0959-5830-489f-ba60-afd4eb0fac36 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c0c1a162-cd30-4ac9-bc62-407493ed54a5 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1c680447-b43a-4ff1-bc64-2c2174ca1c9a (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1e1b7355-4802-d277-e063-6394a90aef44 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1a71964e-e6fa-443e-bfdd-f8852f8cf29e (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:94abdd54-a8e2-4858-8183-6c5d04dbceb5 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a007d945-417c-4647-ab03-95ca219d7d38 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3004aa59-288c-4971-b77b-78789715ef5a (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5fba93fc-4580-48c2-a1ec-5d446680adcf (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5faacbcc-f88f-42f7-8702-791ee82c4d18 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:366134cd-6244-45fc-99f1-0193a0221b3a (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        Elimination The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:27e4ab03-c17b-4268-912c-e45a5e8f8dd8 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ae5d7b3b-e444-48d3-9d85-9b07319f9374 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e4562c70-f245-4dbe-8fe1-0bb64a91a315 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d207396a-068e-4229-88cc-a1a4df7aeff2 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d8b69cc9-bdee-4e24-a3d8-d1887de5a17d (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        Elimination The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c0301841-e209-4242-bace-58a20e6dd01b (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:706a877b-c388-43e7-b083-518111b288b0 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:143ae21e-c350-4c92-b318-7537f4e46596 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:64cd636d-8b48-4f29-b41d-4a048335793e (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bf84ebae-3c91-4448-b1db-8e5ed3053866 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f9af85d3-a5a7-49d6-aff6-1ca2b2d75450 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:35e7bce0-d9ff-4f8b-95c5-218da2a2d929 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        Elimination The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0db22a64-1863-4188-850b-273ea746e327 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:83a6e770-207a-46bc-992d-c1ad90d1006d (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3aff731f-1eec-19b5-e063-6294a90a3143 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e2e50571-d8c1-43e7-b90f-877ba1c35c9b (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:04f9dcdf-4023-48ee-9e7d-ca9366d9db72 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5942a5a8-c3c1-4ecb-921e-9bc92393bdf8 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a5b65a9b-6b8a-48a4-9c72-0e605bb309eb (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      52. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6f919513-500e-4a05-935e-b6fc1615368a (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      53. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3909ac9e-6818-4c5d-ad0e-52865a574b45 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        Elimination The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      54. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:371cb135-6a5f-433d-a87d-ab8521c4aa6d (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      55. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d3ca153c-25b2-4506-91bd-bf9d6a4c01fe (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      56. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed2293f8-2b82-c3db-e053-2995a90ad46c (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      57. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fffb7c59-ad92-4e74-850d-d94d42b7fdc9 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      58. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b950655d-a9f8-4ace-bb56-0c7abbca231e (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      59. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b4a5f170-a400-4986-8c64-f55d0413f0f6 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      60. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dafa7411-2857-4f5a-a587-4367cfbe2bfa (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      61. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:32525ed4-3cca-2b99-e063-6294a90a6c66 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      62. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:733d6e32-ac90-4796-bf25-9d5887c897a5 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        Elimination The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      63. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d4364caf-46c6-4144-9ba5-2c561e4f3a95 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      64. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d5ce687f-4a37-d3e6-e053-2995a90aa974 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      65. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1fce27dd-90a6-45cf-9bd7-13147d3cc0d7 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      66. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:30280d40-28df-4c88-93bd-357a7c528906 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.
      67. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9c3bb751-c425-43ff-b530-2460b568b689 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 to 8 hours.

    2. 5.5 hours

      Numeric value
      5.5
      Unit
      hours
      Source records
      18

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 18 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5b059ef2-dec0-4cea-b8df-d87df3fea9e2 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism Following intravenous infusion of labetalol, the elimination half-life is about 5.5 hours and the total body clearance is approximately 33 mL/min/kg.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1b96ddc9-d0c3-488a-a113-66491fd3d899 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism Following intravenous infusion, the elimination half-life is about 5.5 hours and the total body clearance is approximately 33 mL/min/kg.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:30f9fdef-8781-4327-9a8d-812cb31ff041 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism Following intravenous infusion of labetalol, the elimination half-life is about 5.5 hours and the total body clearance is approximately 33 mL/min/kg.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6cb2c117-584c-4440-acfb-e4b1af4dc509 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        ts subject to bronchospasm, and it may also interfere with exogenous bronchodilators in such patients Pharmacokinetics and Metabolism Following IV infusion of labetalol, the elimination half-life is about 5.5 hours and the total body clearance is approximately 33 mL/min/kg.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a2d07ec0-3718-40eb-9d0a-79c557c486b9 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism Following intravenous infusion, the elimination half-life is about 5.5 hours and the total body clearance is approximately 33 mL/min/kg.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d3579d45-a964-40fe-e3a2-a3a997c8b7b9 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism Following intravenous infusion, the elimination half-life is about 5.5 hours and the total body clearance is approximately 33 mL/min/kg.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:48caf986-3126-48e1-afcd-16d65c9cfe00 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism: Following intravenous infusion of labetalol, the elimination half-life is about 5.5 hours and the total body clearance is approximately 33 mL/min per kilogram.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:da8af6c2-d822-4ae5-9c2d-a1d161bdefd0 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism Following intravenous infusion, the elimination half-life is about 5.5 hours and the total body clearance is approximately 33 mL/min/kg.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fb5ef3ba-0a7e-4f41-9547-d734983da0d3 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism Following intravenous infusion of labetalol, the elimination half-life is about 5.5 hours and the total body clearance is approximately 33 mL/min per kilogram.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:99a715a0-4579-410c-b102-7ef6fab8db55 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        Elimination Following intravenous infusion of labetalol, the elimination half-life is about 5.5 hours and the total body clearance is approximately 33 mL/min/kg.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4a5ffab2-a3b8-411e-992d-7f38d508643a (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism Following intravenous infusion of labetalol, the elimination half-life is about 5.5 hours and the total body clearance is approximately 33 mL/min per kilogram.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:abfc6b75-1ed5-41f1-0484-4597488237bc (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism Following intravenous infusion, the elimination half-life is about 5.5 hours and the total body clearance is approximately 33 mL/min/kg.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e76c4b37-4a34-249d-e053-2995a90aa9be (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism Following intravenous infusion of labetalol, the elimination half-life is about 5.5 hours and the total body clearance is approximately 33 mL/min/kg.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dbf1e4c7-7c0c-4f2f-8cad-96bc6b800cfc (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism Following intravenous infusion, the elimination half-life is about 5.5 hours and the total body clearance is approximately 33 mL/min/kg.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f18dff28-f6f5-4ecb-9797-25062e247559 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism Following intravenous infusion of labetalol, the elimination half-life is about 5.5 hours and the total body clearance is approximately 33 mL/min per kilogram.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d7c53b1c-b6a5-482a-a7c8-7425d9cd9ef8 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism Following intravenous infusion of labetalol, the elimination half-life is about 5.5 hours and the total body clearance is approximately 33 mL/min/kg.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b17a7b3a-e7a5-4987-ae85-ad970e7540c7 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism: Following intravenous infusion, the elimination half-life is about 5.5 hours and the total body clearance is approximately 33 mL/min/kg.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:77152699-1ca8-442a-8cb4-80b0ffbec6f2 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        Pharmacokinetics and Metabolism Following intravenous infusion, the elimination half-life is about 5.5 hours and the total body clearance is approximately 33 mL/min/kg.

    3. 6 hours

      Numeric value
      6
      Unit
      hours
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:63ede355-42ec-4c52-a941-51e5f6b35ed6 (opens source in a new tab)

        Labetalol label

        Version not recorded · Effective date not recorded

        The plasma half-life of labetalol following oral administration is about 6 hours to 8 hours.

  10. Projected row 810

    Medicine slug
    lacosamide
    Compared field
    bioavailability
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    74
    Source count
    74
    Agreement rate
    1
    Recorded readings

    1. 100%

      Numeric value
      100
      Unit
      %
      Source records
      74

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 74 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7ed5cebe-470e-48a4-86ec-2ce79cc32688 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ba337b2c-7c1f-4f7b-ba93-054f502400f3 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e969b294-48d9-42a2-a093-0ac715142460 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:325df1b7-4908-0c03-e063-6294a90ad844 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fb8235b4-4cd3-6f22-e053-6294a90a545c (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2c53d6c3-fe18-dce6-a710-cb874fbf0c59 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:47ae2f1f-d135-4f4e-acc2-500c1afa7b8b (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b4f2620a-2047-4b33-bb75-18702f6c55e6 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5c03b90e-6985-4005-b6c5-44626d0600d7 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7197c0b6-5bb9-43b3-be1d-e7615629df9a (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:07b7b3f2-16a0-4deb-883b-10522676d966 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e3658b3c-f193-41a2-acc7-0bb912e27173 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0a273024-c2d2-4fae-90c3-b2f38a323f24 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:07356cf2-224b-40d2-b827-e10a6b42c232 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:614490ce-a62c-4222-8e4b-ce802cf63028 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:779d2381-f590-45f9-a191-f44af821f4c8 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b9a0ca8c-593c-48e8-b2a7-d30d5f6e6a9b (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:00203a7b-e774-45f7-ac6b-48db6d32a48a (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:419ff519-2b19-4fb9-adfa-868ba0229407 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d98ec7ed-353f-4d4f-9ccd-57ddc62edd0d (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4ae87834-05d8-43c8-aaa3-78047d4a573c (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide oral solution is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3ba29442-4e8a-c2b2-e063-6294a90a1bbf (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide oral solution is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:46b98d5e-fdb6-483a-b022-8b1f0aa832c5 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:024bca92-cac5-4832-a1ff-c1b3d5994ba0 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e265fd09-8149-4423-a317-5760d34b8e9b (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9d7fde23-dc3f-41e9-89cf-6a1a9eeaa7de (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:145b4fae-ce6d-43e8-a474-fcb9dff92a53 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c7793da3-787b-4364-9192-7caab49066f1 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f047077c-2ac7-30d0-e053-2995a90ae429 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2d999f1f-11c6-bc28-e063-6394a90a4a52 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f9aa6154-5d80-4597-90c3-cec131b455d4 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:973cea8d-e516-4014-a116-c5990554a550 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ae9f4f1b-574d-4c9a-80cb-189ccb232723 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8d2906e3-d059-425d-b971-29423963c2af (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:28a594e7-e89b-4d2c-b508-11a5f74700d3 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c5b91128-f838-4e98-9684-5f477fc7af06 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6140b3f1-ff60-427c-91d7-15af99fd78f1 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:45786c84-51ef-4440-bc88-2501951e4c41 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3680c0ff-7f5c-4572-b1eb-4fea96b7fbe2 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d823fbfa-8ff5-4ef8-84ce-fbe916d4e430 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:458e80da-8fc1-4715-9b4b-bc4f388f933f (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:035d85e5-8688-4390-bd55-74baa91c0e9d (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9dffda6c-9e44-478f-9e02-9da3ab4c50e1 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:446f14be-5d79-26b9-e063-6294a90ae0b5 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide oral solution is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:df1d2e6a-6129-49c9-b2c1-0fdf73f38b9c (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cd5ac33e-6ac5-772b-2ead-d66cbd5bd1b4 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:edd20b60-6265-4c4e-a95a-aaf8103cd852 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a024081a-e131-4e88-967d-40155651a945 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:75de00d8-d2e7-4025-be4e-f49299068e7e (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide oral solution is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bbd80370-3d23-41f8-8914-c6ea897c0154 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ba4e2e28-7dc3-47b3-9c2c-34e0b1f39fb8 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      52. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0e21389b-2f51-4975-aa21-fc5c9dd9f6dc (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      53. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7f37f8b8-07d3-48c4-a0c4-7652b62a1ad9 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      54. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f7ea3ce6-4ca7-4405-a011-48e7d71360a5 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      55. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:01162e2f-967b-4596-8188-c0d9889c3814 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      56. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ec1c5ddb-1143-7e6a-e053-2995a90a8382 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      57. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bc7ed8a6-acce-48f2-9ef1-4e366c71dbbc (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      58. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:61e3747a-3957-4840-81f0-313aefbd5d2b (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      59. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cb29da34-89aa-405a-8fbc-2308bda37187 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide oral solution is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      60. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e24d3c45-a559-4fca-a7be-74ce37a7066e (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      61. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9e79b42c-38a3-4b2c-a196-a5a1948250e2 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        VIMPAT is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      62. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:16a9afd2-35a6-44a9-b1d9-ca195c8640d7 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      63. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c83d2156-4dde-4316-98f1-b3dc751f3eac (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      64. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ecb8b33e-7cbd-4f5e-9fe9-e72dff9bcb86 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      65. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2098d3a5-776e-4b52-8ade-80a3ab7b3de7 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      66. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6b4536d0-5703-42b0-9f59-46a3e1b75b22 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      67. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fe24b28b-ca15-4dfd-a198-53cdc2c8cb99 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      68. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f4ffa3ad-1278-4772-9ef8-ed6fdaa47605 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      69. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:68033c90-d9cc-4d5f-896c-9a61a0c3b529 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      70. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:08ac486a-4f61-4e9e-9683-d1a66a6c2a4d (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      71. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:41f02424-231d-4039-a122-df4b49dc9998 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      72. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:19060029-c158-4a37-9261-cfe3b2b5b1e3 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      73. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:264c3718-67ea-4483-b036-2514c853635a (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.
      74. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:48fcaa27-baaa-446e-a282-0c3e232cd151 (opens source in a new tab)

        Lacosamide label

        Version not recorded · Effective date not recorded

        Lacosamide is completely absorbed after oral administration with negligible first-pass effect with a high absolute bioavailability of approximately 100%.

Access

Query or download the projection

View this filtered page as JSONDownload up to 200 filtered CSV rows
GET /api/datasets/source-consensus?limit=10&offset=800

Allowed query parameters

q
Case-insensitive text search over the public fields named for this dataset.
state
Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
field
Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
limit / offset
Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy